Podcasts about Biopharmaceutical

In the latest collaboration between ACRO and TransCelerate BioPharma, Cris McDavid (Senior Director, Global Clinical Operations, Parexel) and Tashan Mistree (Senior Director, Business Operations, Office of Chief Medical Officer, GSK) join this week's episode to discuss the impact of ICH E6(R3) from their different vantage points in the clinical research industry. They dive deeper into their experiences implementing the new guidance at their respective companies, the new opportunities that R3 has created in the partnership between CROs and sponsors, and how they envision the future state of R3 once industry has fully embraced the guidance. FIND ACRO & TRANSCELERATE'S ICH E6(R3) TOOLS & RESOURCES HERE: https://www.acrohealth.org/initiatives-hub/interpreting-ich-e6r3/ 

Send us a textMarc Elia is the Founder of M28 Capital ( https://www.m28capital.com/ ), a healthcare sector investment fund, as well as Chairman of the Board of Invivyd ( https://www.invivyd.com/ ), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, by deploying a proprietary integrated technology platform, to create best in class monoclonal antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Marc has a passion for investing in and developing innovative healthcare solutions, and dedicated much of his career to make a meaningful difference in human health, and advocate for the development of therapies that address unmet medical needs.Prior to M28, from January 2012 to September 2019, Marc served as a partner at Bridger Capital, an investment fund and has served on the Board of Directors of numerous companies.Prior to his time in the healthcare investment space, Marc served in Strategy and Corporate Development roles at Chiron Corporation, in Business Development at Protein Sciences Corporation, as well as in consulting at L.E.K. Consulting.Marc holds a B.A. in economics from Carleton College.#MarcElia #M28Capital #Invivyd #Biopharmaceuticals #InfectiousDiseases #SARSCoV2 #MonoclonalAntibodies #Immunocompromised #RareViralEpitopes #Pemivibart #PreExposureProphylaxis #Covid19 #EmergencyUseAuthorization #EUA #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##New vaccine shows promising results in clinical trialsA new vaccine for a common virus has shown promising results in clinical trials, with a high efficacy rate and minimal side effects. This development could potentially revolutionize the way we prevent and treat this virus in the future.##FDA approves groundbreaking gene therapy for rare genetic disorderThe FDA has approved a groundbreaking gene therapy for a rare genetic disorder, marking a significant milestone in the field of genetic medicine. This therapy has the potential to transform the lives of patients suffering from this debilitating condition.##Big pharma company announces major mergerA major pharmaceutical company has announced a merger with another big player in the industry, creating a powerhouse in the global pharmaceutical market. This merger is expected to have far-reaching implications for the industry as a whole.##Biotech startup secures record-breaking funding roundA biotech startup has secured a record-breaking funding round, signaling strong investor confidence in their innovative approach to drug development. This funding will allow the startup to advance their research and bring potentially life-saving treatments to market.##Researchers discover new mechanism of action for cancer drugResearchers have discovered a new mechanism of action for a commonly used cancer drug, shedding light on how it effectively targets cancer cells. This discovery could lead to the development of more targeted and effective cancer treatments in the future.##FDA issues warning about potential side effects of popular arthritis medicationThe FDA has issued a warning about potential serious side effects associated with a popular arthritis medication, urging patients to consult their healthcare providers before starting or continuing treatment. This warning highlights the importance of monitoring and reporting adverse reactions to medications.##Biopharmaceutical company announces breakthrough in Alzheimer's researchA biopharmaceutical company has announced a major breakthrough in Alzheimer's research, identifying a promising new drug candidate that could potentially slow or even reverse the progression of the disease. This development offers hope for millions of patients and their families affected by Alzheimer's.##Pharma giant partners with leading research institute to accelerate drug discoveryA pharmaceutical giant has partnered with a leading research institute to accelerate drug discovery efforts and bring innovative therapies to market faster. This collaboration aims to leverage the strengths of both organizations to address unmet medical needs and improve patient outcomes.##Health authorities approve new treatment for rare autoimmune diseaseHealth authorities have approved a new treatment for a rare autoimmune disease, providing much-needed hope for patients who have struggled to find effective therapies. This approval represents a significant milestone in the field of autoimmune medicine.##Biotech company receives grant to develop novel antibioticA biotech company has received a grant to develop a novel antibiotic targeting drug-resistant bacteria, addressing a critical need in the fight against antibiotic resistance. This funding will support the company's research efforts and help bring this potentially life-saving treatment to market.##Innovative technology platform revolutionizes drug deliveryAn innovative technology platform has revolutionized drug delivery, enabling more precise targeting of drugs to specific cells or tissues in the body. This technology has the potential to improve treatment outcomes and reduce side effects for patients across various therapeutic areas.#End of podcast episode

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to announce the company has signed a commercial license agreement with Hokkai Yamato Foods Japan, a leading producer of processed foods such as soups, furikake, and ochazuke. As part of the agreement, Hokkai Yamato has acquired a 10kW Radiant Energy Vacuum (REV™) machine to drive product development and support early-stage commercial production in Japan. This license grants Hokkai Yamato exclusive rights to use EnWave's patented REV™ technology for the production of various food products within Japan. In return, Hokkai Yamato will pay royalties to EnWave, consistent with existing licensing agreements. EnWave will work closely with Hokkai Yamato to optimize product development and ensure long-term commercial success. In addition to expanding its presence in the Japanese food sector, EnWave has also signed a master service agreement with BioTechnique, a U.S.-based pharmaceutical contract manufacturer. This agreement lays the groundwork for BioTechnique to evaluate EnWave's REV™ dehydration technology as a potential alternative to freeze-drying in biopharmaceutical applications. As part of the collaboration, BioTechnique will conduct paid testing of several liquid pharmaceutical products, drying them in vials using pilot-scale REV™ machinery at EnWave's Innovation Center in Delta, British Columbia. If the results prove successful, BioTechnique may choose to acquire its own REV™ equipment to provide dehydration services directly to its network of leading pharmaceutical clients. #proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #FoodTech #BusinessNews #Investing #CEOInterview #Peru #Spain #Blueberry #Snacks #Royalties #TradeMission

เปิดพอดแคสต์เอพิโสดนี้ใน YouTube เพื่อประสบการณ์การรับชมที่ดีที่สุด ในวงการความงามโบทูลินัมท็อกซิน (Botulinum Toxin) คือหนึ่งในผลิตภัณฑ์ที่ได้รับความนิยมสูงสุดทั้งในระดับโลกและประเทศไทย ท่ามกลางการแข่งขันที่ดุเดือดและผู้เล่นรายใหม่ที่เข้าสู่ตลาดอย่างต่อเนื่อง แต่หนึ่งในผู้เล่นที่โดดเด่นที่สุดคงหนีไม่พ้นโบทูลินัมท็อกซินสัญชาติเกาหลีใต้ ซึ่งขึ้นชื่อเรื่องการสร้างสรรค์นวัตกรรมที่พลิกโฉมวงการความงามอย่างต่อเนื่อง The Secret Sauce เอพิโสดนี้ พูดคุยกับ Hyunho Jung, Ph.D. หรือ ดร.จอง นักวิทยาศาสตร์ และประธานเจ้าหน้าที่บริหาร บริษัท Medytox ซึ่งเป็นบริษัท Biopharmaceutical ชั้นนำของเกาหลีใต้ ผู้ค้นพบโบทูลินัมท็อกซินสายพันธุ์ใหม่ และพัฒนาผลิตภัณฑ์ ในรูปแบบสารละลายครั้งแรกของโลก เขาจะมาเล่าถึงเส้นทางจากการวิจัยสู่การสร้างธุรกิจระดับโลก และความร่วมมือกับบริษัทไทยที่ทำให้ Medyceles ก้าวขึ้นเป็นผู้นำตลาดความงามในประเทศไทย ติดตามชมได้ในเอพิโสดนี้

In this insightful episode, Albert Thompson, Managing Director, Digital Innovation at Walton Isaacson (https://www.waltonisaacson.com/), shares his forward-thinking take on where programmatic advertising is headed. He challenges the industry to rethink outdated processes, improve partnerships, and embrace smarter ways of working. Looking ahead to 2025, Albert highlights AI's potential to eliminate inefficiencies, spark creativity, and redefine how brands tell their stories and connect with audiences. Beyond technology, Albert dives into the importance of training—not just for newcomers, but for everyone. He emphasizes that staying curious and continuously learning is the key to staying relevant in a fast-changing, AI-driven world. He shares personal experiences and strategic insights on why companies should prioritize education at all levels to stay ahead of the curve. One of the most exciting parts of the discussion? Albert's take on "agentic AI"—a game-changing concept where AI-powered agents go beyond human capabilities to transform industries. He explores how this shift will impact everything from creative strategy to how brands measure and capture consumer attention. From the evolving role of AI in programmatic advertising to the future of consumer engagement, Albert offers a fresh and engaging perspective on what's next in the digital space. About Us: Our mission is to teach historically excluded people how to get started in programmatic media buying and find a dream job.  We do so by providing on-demand lessons via the Reach and Frequency® program (https://reachandfrequencycourse.thinkific.com ), a dope community with like-minded programmatic experts, and live free and paid group coaching.  We can help 2 ways:  Customized a training roadmap for teams of programmatic traders (https://www.heleneparker.com/workshop/ ), adops, customer success, AMs, etc focusing on campaigns performance increase, cross-departmental communication, and revenue growth overall 

João GonçalvesFaculty of PharmacyUniversity of LisbonLisbon, PortugalPaolo CalicetiDepartment of Pharmaceutical and Pharmacological SciencesUniversity of PadovaPadova, ItalyWhat Is PEGylation and Why Is It Important?We will begin by examining the clinical uses of therapeutic proteins, and their applications in healthcare. Next, we will discuss the inherent limitations of therapeutic proteins, including challenges such as pharmacokinetic (PK) profiles, protein aggregation during storage, and potential immune responses. The session will then delve into the process of PEGylation, where polyethylene glycol (PEG) is conjugated to functional amino acid groups on the protein surface. This modification may enhance the properties of therapeutic proteins, offering advantages in stability, half-life, and immunogenicity.Biopharmaceutical and Immunological Properties of PEGylated ProteinsWe will explore the biopharmaceutical and immunological properties of PEGylated proteins, focusing on how their unique structure and composition impact their function. We will discuss how each PEGylated protein has distinct properties based on PEG architecture, molecular weight and degree of conjugation that cannot be generalized across different pegylated molecules, highlighting the variability in pharmacokinetic (PK) characteristics such as half-life, absorption, distribution, and elimination. These factors can significantly influence clinical outcomes, including dosing intervals and overall therapeutic effectiveness. We will also address the potential clinical advantages and limitations of PEGylation, with real-world examples to illustrate how these proteins are used in practice.Immunogenicity Considerations of PEGylated ProteinsWe will explore the immunogenicity of PEGylated proteins, examining both the potential benefits and risks associated with PEG modification. While PEGylation can trigger immune responses against PEG itself or the PEGylated protein, it can also help mask epitopes and reduce anti-drug antibodies formation. Drug- and patient-related factors that influence immunogenicity risk will also be covered, along with the prevalence and impact of pre-existing anti-drug antibodies (ADAs).We will discuss the potential clinical consequences of immune reactions to PEG or PEGylated proteins, and how the risk of such responses can vary depending on the unique properties of each PEGylated protein. The session will also address strategies to mitigate anti-PEG immunogenicity, as well as approaches for monitoring immunogenicity across different stages of drug development—from preclinical studies to post-marketing surveillance. Additionally, we will explore tools that may help predict therapeutic responses to PEGylated proteins, touching on potential areas for future research.Discussion and ConclusionBy the end of the session, participants will gain a comprehensive understanding of:How PEGylation represents a major technological advancement in the development and optimization of therapeutic proteins.How PEGylation affects both the biopharmaceutical properties and clinical applications of therapeutic proteinsImmunogenicity in the context of PEGylated proteins and the strategies used to manage and predict immune responses.The role of PEGylation in therapeutic outcomes and the future opportunities for innovation in this field.

In this episode of The Rob and Jai Show, Dave LeCause, a renowned biopharmaceutical leader and former VP of Allergan Eye Care, reflects on his remarkable career in ophthalmology. Join us as Dave discusses his journey from leading commercial strategies for billion-dollar brands to mentoring the next generation of innovators. Hear his thoughts on innovation cycles, the evolving landscape of dry eye treatments, and why gene and cell therapies hold the key to ophthalmology's future.In this episode, you'll learn:How Dave LeCause helped shape the commercial success of leading ophthalmic brands.His perspective on dry eye innovation and the market's ongoing growth potential.Why gene and cell therapy excite him as the next frontier in eye care.Insights into the evolving role of strategic partnerships and commercialization strategies in startups.The unique opportunities and challenges facing the eye care sector today.Don't miss this inspiring conversation with one of ophthalmology's most influential leaders. Subscribe to the OIS podcast today!

In this episode, we dive into the world of gene therapy logistics with Cryoport Systems' innovative Elite Ultra Cold shipping system. Mike Dybicz and Khoa Tran are in the hotseat to discuss how their solution addresses critical challenges in transporting temperature-sensitive gene therapies. The pair explain how Cryoport Elite offers extended hold times, exceeding industry standards to ensure therapy viability during unexpected delays. Here, its unique payload holding system provides consistent cooling without direct dry ice contact, maintaining product integrity throughout transit. Security is paramount for these high-value therapies. The system allows for re-icing without accessing the payload, reducing tampering risks. Meanwhile, real-time monitoring tracks key metrics such as temperature, pressure and humidity, providing comprehensive visibility during shipping. Dybicz and Tran also emphasize their collaborative product development approach, working with clients to meet current needs and anticipate future challenges. In addition, they discuss their commitment to sustainability and share insights on upcoming innovations, including the SafePak system and plans to expand the Elite product line. Catch the full episode for more insights!See omnystudio.com/listener for privacy information.

Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs' demand means for the biopharma industry's five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.Why GLP-1 Drugs Are in Demand Competition Between Novo Nordisk and Eli LillyHow Expanding the Conditions GLP-1 Drugs Treats Could Influence Insurance CoverageAre Weight Loss Drugs a Threat to Snack Food Stocks?Big Pharma's Looming Patent CliffHow Medicare Negotiations Impact the Pharmaceutical IndustryWhat is a Biologic Drug?Upcoming Innovations in the Pharmaceutical IndustryWhich BioPharma Drugs Do We Expect to Contract?Big Pharma's Five-Year OutlookBiopharmaceutical Stock Picks Read about topics from this episode. 2024 Biopharmaceutical Industry LandscapeObesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk? Investment Opportunities in the Biopharma Industry Obesity Drug Market: The Next Wave of GLP-1 Competition  What to watch from Morningstar.Is the Fed's Plan to Avoid a Recession Working? Don't Overlook These Crucial Parts of Your Retirement PlanBoating Season Is Over, but Don't Overlook These Recreational Vehicle Stocks5 Ways to Improve America's Retirement Savings Read what our team is writing:Karen Andersen Ivanna Hampton  Follow us on social media.Facebook: https://www.facebook.com/MorningstarInc/X: https://x.com/MorningstarIncInstagram: https://www.instagram.com/morningstar... LinkedIn: https://www.linkedin.com/company/5161/

In this Convo of Flanigan's Eco-Logic, Ted speaks with Maria Cho, CEO of Triplebar, a biotech firm using advanced technology to tackle the urgent issues of food and drug supply. She leads a team in a mission to heal and sustain people and the planet by removing a key bottleneck in the bioeconomy. This is being achieved with a proprietary screening platform to accelerate and innovate food and pharma product discovery.Based in East Bay, San Francisco, she shares with Ted that growing up, she was deeply intrigued by science and wanted to be a medical doctor. She began working as a medical assistant at a doctor's office, where she gained experience in the medical environment. While working as a medical assistant, she came to the decision that she did not want to pursue being a doctor. She realized her passion was more about the process of creating drugs rather than being a prescriber, and began thinking about how to get involved in creating products to help fight diseases worldwide.This discovery led to work and experience in various industries, including sales, research, biopharmaceuticals, and skincare. In her current role as CEO at TripleBar, she is leading a team focused on innovation and strategic growth to address some of the world's most challenging sustainability problems around food and healthcare by developing products that can meet current and future unmet needs for healthy nutrition and better disease treatment outcomes on a global scale. She and Ted delve into how they apply this in food and nutrition to bioactives, functional food proteins and cultured meat, and in pharma to better and novel biologics. Maria also discusses the broader implications of these technologies for the future of food and healthcare industries. She emphasizes the potential for bioengineering to not only solve current issues, but also to foresee and mitigate future challenges. Her vision includes fostering a more resilient and health-conscious global community through the application of science and technology.

In this powerful episode, we sit down with Dr. Peter McCullough, a former program director at a leading academic medical center in Dallas, Texas. When COVID-19 hit, Dr. McCullough took action, creating an early treatment protocol using repurposed drugs and supplements that saved millions of lives by preventing severe illness and hospitalizations. Despite his success, his efforts faced harsh opposition from public health authorities, and his treatment approach was dismissed and banned. Dr. McCullough sheds light on the unsettling truth about the influence of biopharmaceutical companies and government corruption, and shares critical insights on how to protect your health and that of your family in the future. Tune in for an eye-opening discussion on what really happened behind the scenes during the pandemic. Read John Leake and Peter McCullough's book - The Courage to Face COVID-19 - Preventing Hospitalization and Death While Battling the Bio-Pharmaceutical Complex - to learn more. --- Support this podcast: https://podcasters.spotify.com/pod/show/elanie-welch/support

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Clinical trials often fail to meet their enrollment goals and schedules, leading to significant financial losses. A new playbook offers solutions to address common challenges in clinical trial recruitment, including strategies for identifying additional participants, engaging and empowering individuals, and refining protocol criteria. The playbook provides insights on how to rescue trials when misalignment occurs, aiming to help brands in the biopharma industry tell compelling stories, build trust, and drive demand.Penumbra has decided to exit the virtual reality business, resulting in the layoff of 71 employees, as the company shifts its focus back to its core thrombectomy business. Qiagen and AstraZeneca have expanded their companion diagnostic partnership beyond cancer, allowing specialty care providers to perform genotyping during routine clinical examinations. Illumina has received FDA approval for a companion diagnostic cancer test that can identify patients eligible for treatment with specific medications targeting genetic features. Johns Hopkins, CareFirst, and Techstars have launched a healthcare AI accelerator program to support up to 12 startups working on AI tools. Medical sales teams are increasingly investing in training and skills development to adopt a more human-centered approach to sales.Biopharmaceutical company BioMarin has announced its second round of layoffs this year, with 225 employees globally being let go. This comes after changes to the company's C-suite last week and a previous round of 170 job cuts in May. In other news, Novartis is expanding its Sirna therapy Leqvio after successful Phase III study results, while Merck has ended two late-stage studies of Keytruda due to disappointing data. Regeneron is suing Sandoz in federal court to block a biosimilar of its drug Eylea. The pharma industry continues to see changes and challenges, with companies making strategic decisions based on clinical trial results and market conditions.Cognition Therapeutics, a small biotech company, recently announced positive results from a mid-stage Alzheimer's study. However, despite the promising results, the company's share price plummeted, puzzling many. The conflicting narratives surrounding the study highlight the significance of presenting scientific results in a way that reassures investors about the risks involved. The success of clinical trials is crucial for small biotechs in the competitive field of Alzheimer's research. Investor support is essential for advancing treatments for Alzheimer's, as progress cannot be made without adequate funding.The Health and Human Services (HHS) plans to appeal a lawsuit decision regarding online tracking technology. The Northwell-Nuvance merger has been approved by state attorneys general with certain conditions, while McLaren Health Care has restored its network after a ransomware attack. The shortage of mental health providers is being addressed with digital tools, and efforts to combat burnout in healthcare are ongoing.Neurocrine's mixed schizophrenia data disappoint Wall Street despite "positive" results, leading to a 20% slide in shares. The FDA rejection of the first MDMA therapy signals challenges in the psychedelic drug field. Bayer partners with RNA drugmaker Nextrna Therapeutics to develop new cancer therapies. A study suggests that covering Wegovy for heart risk could cost Medicare tens of billions each year.Pfizer has partnered with Flagship's Quotient to utilize genetics in targeting heart and kidney diseases. Moderna is facing tough competition as it tries to determine its next move in the biopharmaceutical industry. Neurocrine Biosciences saw a drop in shares despite meeting the primary endpoint in a mid-stage schizophrenia trial.Lykos Therapeutics faced a setback when the FDA rejected its MDMA therapy for PTSD and laun

Techbio is a field combining data, technology and biology to enhance scientific processes — and AI has the potential to supercharge the biopharmaceutical industry further. In this episode of NVIDIA's AI Podcast, host Noah Kravitz speaks with Chris Gibson, cofounder and CEO of Recursion, about how the company uses AI and machine learning to accelerate drug discovery and development at scale. Tune in to hear Gibson discuss how AI is transforming the biopharmaceutical industry by increasing efficiency and lowering discovery costs.

Clinical Trials in Africa: Opportunities & Benefits for Pharmaceutical Industry - PART 2 VIDEOIn this two-part episode series, I will examine the trends, drivers, and opportunity windows that shape the African clinical industry market dynamics and why industry sponsors should consider Africa in their product development plan and strategy.Download a FREE report using this link. https://lnkd.in/ecaMvj-V

In this insightful episode, we explore the cutting-edge field of glycoengineering and its transformative impact on biopharmaceutical drug design. Join us as we chat with Róisín O'Flaherty, Assistant Professor in the Department of Chemistry at Maynooth University, to uncover the nuances of chemoenzymatic glycogen engineering and its potential to revolutionize therapeutics.Key Takeaways:Understanding Glycoengineering: Discover the three main approaches—genetic, metabolomic, and chemoenzymatic—for modifying glycosylation and enhancing drug properties.Real-World Applications: Learn how industry giants are leveraging glycoengineering to innovate cancer treatments and other therapies.Future of Glycoanalytics: Explore how AI and machine learning are poised to further advance the precision and efficiency of glycoengineering.Don't miss this deep dive into how glycoanalytics is paving the way for more effective and personalized biopharmaceutical drugs. Tune in to understand the future of drug design and the exciting possibilities it holds.Connect with Róisín O'Flaherty:LinkedIn: https://www.linkedin.com/in/roisin-o-flaherty-a67a2b8aTwitter: https://x.com/irishglycogirlNext Steps:Book a free assessment to help you get started with glycoanalytics and glycoengineering at https://bruehlmann-consulting.comDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Navidea Biopharmaceuticals, Inc. (OTC: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the company's pivotal NAV3-33 clinical trial. Dr. Michael Blue, Navidea's Chief Medical Officer, said "Results are not indicative of a commercially viable product.” Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops technology to launch its new SD-WAN offer named SD-WAN Essentials, transforming Enterprise connectivity into a stepping stone to the Cloud. For more information, please visit StockDayMedia.com

Uncover the hidden science behind creating safer, more effective biological drugs! Dive into glycoanalytics and glycoengineering, the secret weapons revolutionizing biopharma.Join us as we talk with Róisín O'Flaherty, Assistant Professor in the Department of Chemistry at Maynooth University, who breaks down the complexities of glycosylation and its pivotal role in drug development.Key Takeaways:Critical Quality Attributes: Understand how glycans influence the function and structure of biopharmaceutical products, enhancing their efficacy and safety.Analytical Techniques: Learn about the three major approaches—native glycoprotein analysis, glycopeptide analysis, and released glycan analysis—each providing unique insights into glycosylation.Future Trends: Discover how automation, AI, and advanced mass spectrometry are revolutionizing glycoanalytics, making it more accessible and precise.Tune in to explore how glycoanalytics is driving the next generation of safer, more effective biopharmaceuticals!Connect with Róisín O'Flaherty:LinkedIn: https://www.linkedin.com/in/roisin-o-flaherty-a67a2b8aTwitter: https://x.com/irishglycogirlNext Steps:Book a free assessment to help you get started with glycoanalytics and glycoengineering at https://bruehlmann-consulting.comDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

In this Emerson Automation Experts podcast, Dave Imming joins Jim Cahill to discuss some of Life Sciences industry trends, the challenges they have introduced, and the role technology can play in addressing them.

Thornton v. Ipsen Biopharmaceuticals, Inc.

In this podcast, Emerson's Jorge Costa and Bruce Greenwald join Jim Cahill to discuss the application of PAT technologies not only within the Life Sciences but across many of the process and hybrid manufacturing industries.

Are you interested in how the latest flow technology is transforming biopharmaceutical manufacturing? Join us for Episode 40 of the Life Sciences 360 podcast, where Harsh Thakkar (@harshvthakkar), CEO of Qualtivate sits down with Bethany Silva (@bethany-silva), Life Sciences Industry Manager at Endress+Hauser. They delve deep into the world of flow measurement, focusing on the cutting-edge single-use flow meters based on the Coriolis principle and how this technology is crucial for the development and production of biologics.

On today's episode of the podcast CEO and co-founder of 908 Devices Kevin Knopp joins as guest, discussing how such acceleration is by virtue of technological advancements, including the buzzword artificial intelligence (AI) and machine learning when it comes to bioprocessing.

Ipsen Biopharmaceuticals, Inc. v. Xavier Becerra

Explore the intricate world of perfusion and its sustainability challenges in the part 2 of this episode. Dive into the operational side of managing vast quantities of media production and storage, and discover smart strategies to address these challenges.Jochen Sieck, Director of Cell Culture Media and Process Development at Merck Life Science, discusses the distinction between facility designs for batch and perfusion bioreactors, shedding light on the need for extensive tank farms to support perfusion.Key Insights:Explore the success of automated perfusion media preparation at the lab scale and its scaling up to a 500L capacity.Discover how advancements in small-scale perfusion operations are supercharging the perfusion process development.Get practical steps for developing a cost-efficient perfusion process.Tune in to discover how perfusion processes are revolutionizing the biotech industry and contributing to a more sustainable future.Connect with Jochen Sieck:LinkedIn: https://www.linkedin.com/in/jochenbsieckACTIP Fellowship award: https://www.actip.org/fellowshipResources:Perfusion Cell Culture Processes for Biopharmaceuticals by Moritz Wolf, Jean-Marc Bielser, and Massimo Morbidelli: https://www.cambridge.org/core/books/perfusion-cell-culture-processes-for-biopharmaceuticals/5C650AD26D52B2435E7796D382ECE5DANext Step:Elevate your biologics development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Explore perfusion processes and sustainability with our guest, Jochen Sieck, Director of Cell Culture Media and Process Development at Merck Life Science.Learn about the evolution of perfusion methodologies, its historical roots in addressing product stability, and its recent return to continuous and integrated manufacturing.Jochen discusses the economic and strategic reasons behind perfusion's resurgence, emphasizing the need for flexible, smaller-scale facilities.Key Learnings:Gain insight into the environmental impact of traditional facilities and the potential benefits of alternatives.Dive deep into the balance of cost, productivity, and sustainability in media consumption.Discover strategies for optimizing perfusion rates and sustainability.Get ready to expand your understanding of perfusion processes, sustainability, and the delicate dance between economics and environmental consciousness.Connect with Jochen Sieck:LinkedIn: https://www.linkedin.com/in/jochenbsieckACTIP Fellowship award: https://www.actip.org/fellowshipResources:Perfusion Cell Culture Processes for Biopharmaceuticals by Moritz Wolf, Jean-Marc Bielser, and Massimo Morbidelli: https://www.cambridge.org/core/books/perfusion-cell-culture-processes-for-biopharmaceuticals/5C650AD26D52B2435E7796D382ECE5DANext Step:Elevate your biologics development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

In this Emerson Automation Experts podcast, Michalle Adkins and Hilary Mills-Baker join me to discuss the challenges of achieving the required data integrity and solutions to drive performance improvements.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Astrazeneca acquired a biotech startup called Amolyt for $800 million, adding a late-stage drug prospect for parathyroidism to its rare disease portfolio. Bio, a lobbying group for the biopharmaceutical industry, changed its stance and now supports a bill to limit China's role in US biotech. German biotech Tubulis secured €128 million in financing to capitalize on the momentum in antibody-drug conjugates (ADCs). J&J and Novo are supporting Asgard's efforts to develop personalized cancer therapies that reprogram tumor cells in the body. The FDA is focusing on early deaths in a meeting regarding broader CAR-T use in myeloma, particularly in trials from Bristol Myers Squibb and Johnson & Johnson. Additionally, there are five questions facing emerging biotech companies as they navigate through the industry's current landscape. The newsletter also covers various topics including the use of AI-enabled digital twins to secure the pharmaceutical supply chain, Medicare coverage of weight-loss drugs, and shifts in the clinical trial landscape.The EPA has issued a final rule limiting ethylene oxide emissions from medical device sterilizers, giving companies two years to comply. Exactech received a warning letter from the FDA regarding faulty implant packaging analysis. US hospitals expect an increase in procedures as staffing pressures ease, potentially benefiting companies like Boston Scientific, Medtronic, and Stryker. The FDA is seeking feedback on expanding premarket cybersecurity guidance. Additionally, AI and digital health trends are becoming more prominent in the medical device industry.AstraZeneca has acquired Amolyt Pharma for $1.05 billion, adding to its rare disease portfolio with late-stage candidate eneboparatide for hypoparathyroidism. The deal also includes ownership of azp-3813, being assessed for acromegaly in a phase I trial. In other news, Vertex failed to convince the UK watchdog of the value of its CRISPR therapy Casgevy, and Wuxi AppTec has been removed from a trade group amid US national security concerns. ADC Biotech Tubulis closed a $138 million financing round to support its lead solid tumor antibody-drug conjugate candidates.The Biden administration has proposed the implementation of "march-in rights" to seize patents for drugs that are priced unreasonably high. This move has sparked debate among stakeholders, with concerns about the potential negative impact on innovation in drug development. Despite efforts to bring down drug prices, critics believe that federal intervention in patent protection could have devastating consequences.The biosimilars market in the U.S. has been limited by patent thickets and insurance contracting, but there are signs of momentum. CVS has launched a new venture in biosimilar drug experimentation, while biosimilar makers are using different strategies to compete with top-selling drugs like Humira. Sandoz has spun out of Novartis to become a standalone generic drugmaker.Thank you for listening to Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.

To kick off the first episode of “The Weekly Bioanalysis” in 2024, Dom and John unveil some fun new things happening at KCAS, by talking about the parallel evolution of the bioanalytical industry and KCAS. Our hosts go way back – almost to “square one” (discussing “What is bioanalysis?” and “How has bioanalysis changed over the years?”. They take a nice little dip back into history and then and then tie it all back to where we are now and what it means about we are going for the future. We hope you enjoy our announcement as much as you enjoy listening to how we've evolved as an industry, as well as an organization.“The Weekly Bioanalysis” is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

For the final episode of “The Weekly Bioanalysis” in 2023, Dom and John invited KCAS's scientific advisory team to join them, as we thought that as we are coming to the end of the year, it might be a good opportunity to introduce a few members of the scientific advisory team who may be involved in some greater capacity with the podcast going forward, as the organization grows and expands. Then our hosts just have a chat about reviewing how 2023 went and what they see coming up in 2024 within the pharmaceutical and biopharmaceutical industries – so a look back, a look at where we are, and a look forward.“The Weekly Bioanalysis” is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

Kathy Ford is the Chief Operating Officer (COO) at Kura Oncology. She has over 30 years experience in biopharmaceuticals. She is equally passionate about the work she does bringing treatment to cancer patients and as a mom and grandmother. Kathy earned her R.N. from Massachusetts General Hospital School of Nursing and her B.S.N. from Fitchburg State College.What do we talk about in this episode?Kathy's journey from nursing, being a stay at home mom, and back into the job market and into executive management in biopharmaceuticals.The changes she has seen for women in medicine and STEM fields over the past several decades.The importance of family in her life. Grandmotherhood is her greatest joy!Her passion for working for a company working to treat and cure cancer.The importance of women, especially in higher positions, using their voice to support other women.What does a COO do?Music used in the podcast: Higher Up, Silverman Sound StudioYou can support my podcast on Patreon here: https://patreon.com/user?u=72701887ResourcesHematologic cancers begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer include leukemia, lymphoma, and multiple myeloma. It's also referred to as blood cancer. (https://www.summitcancercenters.com/cancers-we-treat/hematologic-cancer/#:~:text=Hematologic%20cancers%20begin%20in%20blood,referred%20to%20as%20blood%20cancer.)Some 37% of active physicians in the U.S. were women in 2021, up from about 36% in 2019, and about 47% of residents and fellows were women, according to the AAMC report.Large gender pay gaps still exist, however. A 2021 report from the Rand Corporation published in Health Affairs found female physicians earn $2 million less than men over the course of their career, with the largest gaps in male-dominated specialties. (https://www.healthcaredive.com/news/AAMC-us-physician-workforce-women-specialties/640621/#:~:text=Some%2037%25%20of%20active%20physicians,according%20to%20the%20AAMC%20report.)

Dom and John have been doing this for a long time (for over 70 episodes now, to be exact), but they felt it might be a good idea to jump back to the very beginning and discuss the overarching concept of the Drug Development process and where it is that Bioanalysis fits in. This is somewhat of a response to a recent listener request, but we also feel its important every once in a while to refocus and put all of the things we do at KCAS into perspective against the entire pharmaceutical and biotech industry – from large and small molecule and GLP vs Non-GLP, to all the therapeutic areas with drug development, Dom and John discuss it all on episode #71 of “The Weekly Bioanalysis”"The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

• Susan Stipa, with a diverse background in pharmaceuticals, biotechnology, and financial services, discusses the evolution of her career and her transition into marketing, emphasizing her passion for blending scientific understanding with creative communication. • She highlights the rapid and transformative advancements in biopharmaceuticals, touching on the challenges and excitement surrounding emerging therapies like cell and gene therapy and expressing concern about ensuring access to these innovations. • Susan mentions the importance of effective communication within the biotech industry, especially when engaging with journalists to accurately relay complex scientific concepts, showcasing CG Life's role as a mediator to foster better understanding. • She reflects on valuable leadership advice received from her father about making a strong initial impression and the importance of human connection, opposing a rigid corporate mentality, to foster creativity and meaningful relationships. • Both Susan and the host, Don, share an appreciation for the relentless drive within the biotech industry and its potential to address global health challenges, emphasizing the fulfillment derived from their roles in this dynamic field.

America Out Loud PULSE with Dr. Peter McCullough and Malcolm – In regards to these turbo cancers we've seen people having, do you have an idea of how close the onset is in regards to the time a person gets the jab and then cancer? How can I find out if I have Spike Protein or mRNA in my blood? Do you recommend ECGs for young teens and adults getting sports physicals?

America Out Loud PULSE with Dr. Peter McCullough and Malcolm – In regards to these turbo cancers we've seen people having, do you have an idea of how close the onset is in regards to the time a person gets the jab and then cancer? How can I find out if I have Spike Protein or mRNA in my blood? Do you recommend ECGs for young teens and adults getting sports physicals?

It is that time of year once again... the Fall Conference Season! Every industry has its own set of important trade shows and meetings, but for the Pharma, biotech and bioanalytical industries, these conferences are an opportunity for the planet's leading experts to get together and share the newest ways to heal the world. With October almost upon us, Dom and John discuss the upcoming conferences in our industry, and why it might be worth your time to find yourself at more than one of them - it might even be a chance to meet Dom and John there!"The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

What are some strategies that companies can use to get to IND filing quickly? In this brand new conversation, Evaluating Biopharma podcast host Ben Locwin discusses the risks and rewards of speed-to-IND strategies with Susan Jones, Chief Technology Officer at Tourmaline Bio. Susan delves into her 30 years of experience in the biotech industry, how quality by design impacts IND filing, and the pitfalls of using platform approaches to accelerate early development. Finally, she shares some case studies where accelerated timelines led to unexpected outcomes, as well as advice on knowing your situation and risks, and spending time understanding your molecule first. Links from this episode:  Evaluating Biopharma  Black Diamond Networks Tourmaline Bio Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today's decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary information to make better business and process decisions. The Evaluating Biopharma podcast is a reproduction of content originally presented at recent Evaluating Biopharma digital and educational networking events.

Shawn Singh: https://www.linkedin.com/in/shawnsingh/Vistagen: https://www.vistagen.com/To learn more about BCLA and our events, check out: https://www.bc-la.org

In this ACT ToxChats© episode, Dr. Meredith Steeves and Mr. Terry Leyden share their perspectives on the current hiring landscape for toxicologist roles in industry, how to find the right fit, tips for transitioning from a bench-based position, and how to prepare for and successfully navigate the interview and negotiation process. Dr. Steeves and Mr. Leyden have complementary roles in the hiring process for toxicologists in the biopharmaceutical industry. Dr. Steeves is a Senior Director of Toxicology and hiring manager at Eli Lilly and Mr. Leyden is a Certified Personnel Consultant and President of The Leyden Group, a Colorado-based professional recruiting and search firm. This podcast is of interest for toxicologists at all career stages, with a specific focus on trainees and early career professionals and is presented by the ACT Early Career Professional Subcommittee.

Starting off with a description of Antibody Drug Conjugates (or ADCs, for short), Dom and John dive into this field of the industry and discuss the ways these services have changed over time and even how they've changed recently. They review the role of ADCs in meeting some of the unmet medical needs in oncology and the way they're changing the effectiveness of some of the most modern drugs being developed. The evolution of ADC design for approved medications and indications make it clear that Antibody Drug Conjugates will be a big part of our industry for a long time."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

Leonard Mazur, founder and CEO of Citius Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Citius is working to unlock the potential of first-in-class critical care therapeutics, with a pipeline of anti-infectives in oncology, adjunct cancer care and stem cell therapy.

In this episode of "That's Understandable," Liz Bodin, Vice President, US Respiratory & Immunology, and Mariam Koohdary, Deputy General Counsel, BioPharmaceuticals, join Brendan to shed light on the challenges and triumphs of women in leadership roles within the healthcare industry. They discuss the importance of diversity, the role of mentorship, the drive to innovate and how we can all agree – the struggle is real.To learn which screenings are appropriate for you, we encourage you to visit the US Preventive Services Task Force. The US Preventive Services Task Force is an independent, volunteer panel of national experts in disease prevention and evidence-based medicine. It works to improve the health of people nationwide by making evidence-based recommendations about clinical preventive services and prolong life.

Synopsis: Jim Brown is the President and CEO of DURECT Corporation, a biopharmaceutical company committed to transforming the treatment of acute organ injuries and chronic liver diseases by advancing novel and potentially lifesaving epigenetic therapies. Jim discusses how his early beginnings as a vet ultimately led him to the biotech industry. He talks about epigenetic regulation and how it ties into the work DURECT is leading. He dives into the unmet need for treatment for chronic liver diseases and how he gets capital markets to understand the potential impact in an area where there isn't a lot of awareness. He also discusses where the company is from a development perspective, their plans to commercialize, and his advice to other entrepreneurs and leaders as they navigate the inherent risk that's involved in developing a new therapeutic. Biography: James E. Brown, D.V.M., co-founded DURECT in February 1998 and has served as President, Chief Executive Officer, and a Director since June 1998. He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995, Director of Joint Ventures for Discovery Research from April 1992 to May 1995, and held a number of positions, including Program Director, for Syntex Research and Development from October 1985 to March 1992. Dr. Brown holds a Bachelor of Arts from San Jose State University and a Doctor of Veterinary Medicine from the University of California, Davis, where he also conducted postgraduate work in pharmacology and toxicology.

Freedom International LivestreamOn June 8, 2023 Thursday Guest: Dr. Norman Fenton Topic: “Five Stages of Academic Censorship by the Biopharmaceutical Complex” Auto-Bio: “I am Professor Emeritus of Risk at Queen Mary University of London (retired as Full Professor Dec 2022) and a Director of Agena, a company that specializes in artificial intelligence and Bayesian probabilistic reasoning. I'm a mathematician by training with current focus on quantifying risk and uncertainty using causal, probabilistic models that combine data and knowledge (Bayesian networks). I have published 7 books and over 400 peer reviewed articles. My works covers multiple domains including especially law and forensics (I've been an expert witness in major criminal and civil cases), and health. Since 2020 I have been active in analysing data related to Covid risk.” What we Discussed: - Why he Started Studying Covid ( 4mins) - When he Realised there was Censorship - The use of Ai for Censorship (16:30min) - The Uk Data was not as show - How captured are the Journals ( 22mins) - The BBC Documentary Propraganda (25mins) - The Flu went on Vacation (31 mins) - Heiko Schoening showing it was a Plandemic (33 mins) - The W.H.O. Getting more power (35:45 min) - More People are Waking Up with Vax injuries( 40 mins) - Don't depend on the State ( 47mins) and more Interview Panel TIP/DONATE LINK for Grace Asagra @ Quantum Nurse Podcasthttps://patron.podbean.com/QuantumNursehttps://www.paypal.com/donate/?hosted_button_id=FHUXTQVAVJDPU Grace Asagra, RN MA (From Start to 21:30 mins) Podcast: Quantum Nursewww.quantumnurse.life Quantum Nurse Podbean https://graceasagra.podbean.com Roy Coughlan (from 21:30 mins to 44 Mins)Podcast: AWAKENINGhttps://www.awakeningpodcast.org/ TIP/DONATE LINK for Roy Coughlan @ Awakening Podcasthttps://www.awakeningpodcast.org/support/ Hartmut Schmacker ( 44 mins to 1Hr8mins) How to Contact Dr. Norman Fenton: https://www.normanfenton.com/ ====================== More about Roy: All Podcasts + Coaching and Social Media https://bio.link/podcaster https://awakeningpodcast.org/ Donations  https://www.awakeningpodcast.org/support/ Video https://www.bitchute.com/channel/y2XWI0VCPVqX/ https://rumble.com/user/Awakening

The McCullough Report with Dr. Peter McCullough – What was unique about his case is that the alleged misinformation was done out of a personal financial conflict of interest to promote the Institute's "Campaign for Cures" to develop a competitive vaccine. The alleged public misinformation he was accused of was that the COVID-19 vaccines were ineffective...

The McCullough Report with Dr. Peter McCullough – What was unique about his case is that the alleged misinformation was done out of a personal financial conflict of interest to promote the Institute's "Campaign for Cures" to develop a competitive vaccine. The alleged public misinformation he was accused of was that the COVID-19 vaccines were ineffective...

The McCullough Report with Dr. Peter McCullough – This is an emotionally gripping interview and story of a father and mother who a few years earlier lost their son to suicide and now their daughter Grace, who may have turned the corner on acute COVID-19 but instead had her life snuffed out with a trio of drugs that suppressed her...

The McCullough Report with Dr. Peter McCullough – In the last several weeks, the United States Congress, with multiple witnesses, established that the origin of SARS-Co-V2 was the Wuhan Institute of (WIV)  Biosecurity Annex Level 4 lab in Wuhan, China. In my view, the Senators missed asking five key question sets...

The McCullough Report with Dr. Peter McCullough – In the last several weeks, the United States Congress, with multiple witnesses, established that the origin of SARS-Co-V2 was the Wuhan Institute of (WIV)  Biosecurity Annex Level 4 lab in Wuhan, China. In my view, the Senators missed asking five key question sets...

Biopharmaceutical innovators responded heroically to the COVID-19 pandemic. In unprecedented time and with cutting-edge technologies, they created vaccines and other medical treatments that saved millions of lives around the world. For this extraordinary achievement, leftists and libertarians have vilified them, and politicians are actively seeking to confiscate their patents. This talk explains how patents made possible the unprecedented response to the pandemic and why these vital property rights have been wrongly attacked. Recorded live on July 7, 2022 as part of the Objectivist Summer Conference.